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AbstrACt
Introduction Type 2 diabetes mellitus (T2DM) is one 
of the leading causes of death and disability worldwide, 
generating substantial economic burden for people with 
diabetes and their families, and to health systems and 
national economies. Bangladesh has one of the largest 
numbers of adults with diabetes in the South Asian region. 
This paper describes the planned economic evaluation of 
a three-arm cluster randomised control trial of mHealth 
and community mobilisation interventions to prevent 
and control T2DM and non-communicable diseases’ risk 
factors in rural Bangladesh (D-Magic trial).
Methods and analysis The economic evaluation will 
be conducted as a within-trial analysis to evaluate the 
incremental costs and health outcomes of mHealth and 
community mobilisation interventions compared with the 
status quo. The analyses will be conducted from a societal 
perspective, assessing the economic impact for all parties 
affected by the interventions, including implementing 
agencies (programme costs), healthcare providers, and 
participants and their households. Incremental cost-
effectiveness ratios (ICERs) will be calculated in terms 
of cost per case of intermediate hyperglycaemia and 
T2DM prevented and cost per case of diabetes prevented 
among individuals with intermediate hyperglycaemia at 
baseline and cost per mm Hg reduction in systolic blood 
pressure. In addition to ICERs, the economic evaluation will 
be presented as a cost–consequence analysis where the 
incremental costs and all statistically signiicant outcomes 
will be listed separately. Robustness of the results will 
be assessed through sensitivity analyses. In addition, 
an analysis of equity impact of the interventions will be 
conducted.
Ethics and dissemination The approval to conduct the 
study was obtained by the University College London 
Research Ethics Committee (4766/002) and by the 
Ethical Review Committee of the Diabetic Association of 
Bangladesh (BADAS-ERC/EC/t5100246). The indings of 
this study will be disseminated through different means 
within academia and the wider policy sphere.
trial registration number ISRCTN41083256; Pre-results.
bACkground 
burden of diabetes mellitus
Diabetes mellitus, mainly type 2 (T2DM), 
is one of the leading causes of death and 
disability worldwide. It is estimated that 
strengths and limitations of this study
 Ź This protocol paper reports planned data collection 
and analyses alongside a complex public health trial 
to ensure transparency.
 Ź This protocol can assist in designing mHealth and 
community mobilisation through participatory 
learning and action approach interventions for the 
prevention of diabetes and mitigation of non-com-
municable diseases risk factors.
 Ź The protocol, and planned analysis and reporting fol-
low recommended guidelines to design and report 
economic evaluations.
 Ź An equity impact analysis and contingent valuation 
study will be conducted alongside the study.
 Ź The study is powered to assess the cost-effective-
ness of each intervention against control only. The 
study is not powered to test the differences between 
the mHealth and community mobilisation inter-
ventions. Therefore, it will be possible to estimate 
incremental cost and effect of each intervention 
compared with the control only.
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around 415 million people worldwide or 9% of adults 
aged 20–79 have diabetes, with about 75% of people 
living with diabetes residing in low-income and middle-in-
come countries (LMICs).1 It is predicted that by 2040, 1 
in 10 adults will have diabetes, unless preventive efforts 
are undertaken.1 Diabetes, if not managed properly, can 
lead to several complications, such as heart attack, kidney 
failure, leg amputation, vision loss and several other long-
term consequences, that impact significantly on quality 
of life and cause premature death.1 2 Diabetes and its 
complications create a substantial economic burden for 
people with diabetes and their families, and for health 
systems and national economies through direct medical 
costs and productivity loss.2 It is reported that in many 
countries between 5% and 20% of total health expendi-
ture are spent on diabetes.1 This is in addition to the large 
financial burden on individuals and their families due to 
the cost of seeking care.
Bangladesh has the second largest number of adults 
with diabetes in the South Asian region, with around 
7 million adults aged 20–79 years with diabetes.1 The 
prevalence of diabetes among adults (20–79 years old) in 
Bangladesh is estimated to be around 8.5%,1 2 with a three 
to fourfold increase since the 1990s.3 4 It is predicted that 
prevalence of diabetes in Bangladesh will reach 23.6% 
in men and 33.5% in women by 2030, unless preventive 
efforts are undertaken.3 The increasingly high incidence 
of diabetes in Bangladesh has had a significant economic 
burden, in particular for people with diabetes, their fami-
lies and the country’s healthcare system. It is estimated 
that the annual health expenditure for diabetes is around 
US$218 million, where most of the costs born by the 
families.5
Underlying the increasing prevalence of diabetes, 
globally and in Bangladesh, are complex genetic, envi-
ronmental and lifestyle factors, including changes in 
dietary habits and increases in risk factors like smoking 
and physical inactivity.2 Effective interventions are avail-
able to prevent T2DM and to prevent the complications 
and premature death from diabetes.2 The evidence from 
LMICs shows that lifestyle and other non-pharmacological 
interventions can prevent and delay the onset of T2DM 
and its complications.6 However, there is a lack of cost-ef-
fective programmes designed specifically for Bangladeshi 
populations, taking into account their contextual needs 
and resources.
the bangladesh d-Magic trial
The Bangladesh D-magic is a three-arm cluster randomised 
control trial (cRCT) of mHealth and community mobili-
sation interventions, conducted in four rural upazilas in 
Faridpur district, Bangladesh. The trial aims to assess the 
effectiveness and cost-effectiveness of the interventions 
in the prevention and control of T2DM and non-com-
municable disease (NCD) risk factors in rural Bangla-
desh. In the D-magic trial, the clusters (96 villages) were 
randomised to receive either the mHealth intervention, 
the community mobilisation intervention or be in the 
control arm (32 in each). In the mHealth intervention, 
individuals receive voice messages about prevention and 
control of NCD risk factors and T2DM on their mobile 
phone. In the community mobilisation intervention, a 
trained facilitator initiates a series of diabetes and NCD 
risk factor focused monthly group meetings for men and 
women, working through a participatory learning and 
action (PLA) cycle by which group members themselves 
identify, prioritise and tackle problems associated with 
T2DM and its risk factors. In addition, all study areas 
(both intervention and control) clusters receive health 
system strengthening (HSS) activities, which include 
the training/refresher training of healthcare workers 
working in the community and health facilities, in the 
prevention, diagnosis and treatment of T2DM, as well as 
the development of essential equipment inventories.
Details of the D-Magic trial are described elsewhere.7 
This protocol paper aims to fully describe the method-
ology for the economic evaluation of the trial.
Economic evaluations of community and mHealth 
interventions for prevention and control of diabetes
There is evidence that mHealth programmes can have a 
positive impact on behavioural change and prevention 
and control of diabetes and NCDs in high-risk popula-
tions.8–11 However, there is little information on the cost 
and cost-effectiveness of mHealth interventions for the 
prevention and control of NCDs.12–14 Two recent system-
atic reviews of the economic evidence of mHealth13 and 
mHealth for diabetes prevention and control14 have 
shown that there are a handful of NCD and diabetes inter-
ventions that have reported cost and cost-effectiveness 
evidence. Nearly, all of these studies have been conducted 
in high-income settings. The majority of these studies 
report that mHealth interventions are cost-effective or 
cost saving, though the quality of reported evidence was 
not satisfactory in some of cases.13 14
Similarly, although there is some evidence on effective-
ness of community-based interventions in the manage-
ment of T2DM in low-income settings,15–19 there is little 
evidence on how cost-effective these interventions might 
be.14 A recent review14 has identified 10 community-based 
interventions on preventing and controlling diabetes. 
These interventions, which are largely implemented 
in high-income settings, have reported that communi-
ty-based interventions are cost-effective or cost-saving 
approaches in the management of T2DM.14
The current study will be the first to assess the cost-effec-
tiveness of community mobilisation through PLA in the 
prevention of T2DM. This approach has previously been 
shown to be highly cost-effective in improving maternal 
and newborn health.20 21 This study will also contribute to 
the evidence on cost-effectiveness of mHealth interven-
tions for preventing T2DM in LMIC settings.
Aim and objectives
The D-Magic economic evaluation aims to measure 
the cost-effectiveness of mHealth and participatory 
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community group interventions to prevent and to control 
T2DM and NCD risk factors in rural Bangladesh from a 
societal perspective.
The specific objectives of the D-Magic economic evalu-
ation are:
1. To estimate the costs of setting up and implementing 
the mHealth and participatory community group in-
terventions as well as HSS activities.
2. To calculate the costs to the healthcare system, of in-
creased care-seeking (ie, diagnosis and treatment) for 
T2DM and other NCDs, as a result of the D-Magic in-
terventions.
3. To measure costs associated to the intervention par-
ticipants and their households of changes in diabe-
tes or other NCD-related diagnosis and management 
care-seeking costs as well as any costs associate with 
changes in diet and other lifestyle behaviours, as a re-
sult of the D-Magic interventions.
4. To present the incremental costs and outcomes of the 
interventions as a cost–consequence analysis.
5. To calculate the incremental cost-effectiveness of the 
mHealth and community mobilisation interventions 
combined with HSS activities, as compared with HSS ac-
tivities alone, where all new HSS activities are delivered 
in addition to the existing government programmes.
In addition to the above-mentioned objectives, the 
equity impact of the mHealth and community mobilisa-
tion interventions will be assessed.
MEtHods
study setting and population
The study setting for the D-Magic trial is Faridpur district, 
located South of Dhaka. The district has a population of 
over 1.7 million people in a high-density area of just over 
2000 km2. It is primarily an agricultural economy, with the 
main crops being jute and rice. Like in the rest of Bangla-
desh, healthcare is provided at three levels: primary 
care is provided at Community Clinics and at Union 
Health and Family Welfare Centres; secondary level care 
providers (both inpatient and outpatient services) are 
subdistrict (upazila) health complexes and hospitals; and 
tertiary care is provided at district hospitals and medical 
college hospitals.22 Private and informal service providers 
are also present in the area, with the informal sector 
being the main provider in rural areas,22 Faridpur district 
included. Inadequate and inequitable access to services, 
shortages of skilled healthcare providers, short supplies 
of medicines and poor quality and low responsiveness of 
services are the main challenges faced by the Bangladesh 
healthcare system,22 and remains a challenge in Faridpur 
district too.
The study population for the D-Magic study is men and 
non-pregnant women who are aged 30 years or more 
and permanent residents (ie, lived there for more than 
6 month) of 96 villages (clusters) in four rural upazilas—
Nagarkanda, Boalmari, Saltha and Madhukhali—in 
Faridpur district.
trial design
The D-Magic trial is a three-arm cRCT which is imple-
mented in four rural upazilas in Faridpur district, 
Bangladesh. In D-Magic trial, 96 clusters (villages) were 
randomised to receive either the mHealth intervention, 
the community mobilisation intervention or be in the 
control arm. All three arms receive a number of HSS 
activities. The interventions implementation was started 
in July 2016 and was completed by end of December 2017 
and all data collection was completed in June 2018.
Detailed information on the randomisation and partic-
ipants recruitment process, trial timeline, and a full 
description of the interventions is presented elsewhere.7 
A brief description of the mHealth, community mobilisa-
tion and HSS interventions are presented in the following 
sections.
mHealth intervention
The mHealth intervention involves free of charge voice 
messages about the prevention and control of T2DM 
and NCD risk factors sent two times per week to the indi-
vidual’s mobile phone during a 14-month period. The 
intervention and the messages’ content were developed 
based on findings from baseline formative research in 
the study area and application of the behavioural change 
theories such as the Capability, Opportunity, Motiva-
tion, Behaviour (COM-B) model for understanding 
behaviour23 and the Theoretical Domains Framework 
(TDF) to encourage change.24 25 The mHealth inter-
vention is available to all individuals who have access to 
a mobile phone and registered to receive the messages 
by providing their mobile number to the intervention 
community recruiters.
Community mobilisation intervention
The community mobilisation intervention involves initi-
ation and facilitation of separate male and female partic-
ipatory groups, with approximately 20 members in each. 
The intervention is an adaptation of a participatory 
women’s groups intervention implemented in South 
Asia (including Bangladesh) and Sub-Saharan African 
settings and shown to be effective and cost-effective at 
reducing neonatal mortality.20 26 The groups progress 
through a series of 18 monthly meetings following the 
four phases of PLA. During phase 1, participants iden-
tify and prioritise factors that affect their health, partic-
ularly those increasing their risk of developing or failing 
to manage T2DM; in phase 2, the participants and their 
community come up with feasible strategies that can 
be implemented to address the problems identified in 
phase 1; during phase 3, they implement these strate-
gies; in phase 4, they evaluate the strategies they have 
implemented. The groups are run by salaried facilita-
tors, who are recruited from the study areas and have 
a minimum of higher secondary school education. The 
facilitators undertook 1-week training on group facilita-
tion and basic health messages related to NCD preven-
tion and control, in particular T2DM. They also have 
Protected by copyright.
 o
n
 Septem
ber 25, 2019 at The Librarian J B M
orrell Library.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-022035 on 20 August 2018. Downloaded from 
4 Haghparast-Bidgoli H, et al. BMJ Open 2018;8:e022035. doi:10.1136/bmjopen-2018-022035
Open access 
received refresher training during the course of the 
interventions.
Health systems strengthening
A series of HSS activities are carried out in all study areas 
(both intervention and control clusters). These activities, 
which are tailored according to the mapping of healthcare 
providers in the project area in the formative phase of the 
project, included the training of mainly informal health-
care workers in the community and distributing educa-
tional materials among formal and informal providers in 
prevention, diagnosis and treatment of T2DM, as well as 
the development of essential equipment inventories.
Measurement of health outcomes/effectiveness
The D-Magic trial will test the effect of the community 
mobilisation intervention and mHealth intervention 
relative to the control and does not directly compare the 
effects of each intervention relative to the other. As this is 
a cluster randomised trial, the outcomes will be measured 
among individuals (permanent residents) who live in the 
intervention clusters, irrespective of whether they took 
part in groups or received mHealth messages. Analysis 
of the outcomes will be by intention to treat at the indi-
vidual and cluster level as appropriate. Moreover, partici-
pants with missing data on the primary outcomes will be 
excluded from primary outcome analysis.7
Primary outcome
The D-Magic trial has two primary outcomes: combined 
prevalence of intermediate hyperglycaemia (ie, impaired 
fasting glucose or impaired glucose tolerance) and T2DM, 
and cumulative 2-year incidence of T2DM among individ-
uals identified with intermediate hyperglycaemia at the 
start of the trial.7 Using the prevalence data, the number 
of intermediate hyperglycaemia and diabetes mellitus 
cases prevented, and the number of diabetes cases 
prevented among individuals with intermediate hyper-
glycaemia at baseline will be calculated as the difference 
between the expected and the actual number of cases 
using the adjusted OR relative to the control population.
Secondary outcomes
The trial has a number of secondary outcomes including 
diastolic and systolic blood pressure (BP), prevalence of 
hypertension, body mass index, prevalence of overweight 
and obesity, prevalence of abdominal obesity, health-re-
lated quality of life, and psychological distress among 
self-reported diabetics.7
Comparison will be made between the interventions 
(mHealth and community mobilisation) and control 
(HSS activities only) to estimate incremental cost-ef-
fectiveness ratios (ICERs) for the primary outcomes; in 
terms of cost per case of intermediate hyperglycaemia and 
diabetes mellitus prevented and cost per case of diabetes 
prevented among individuals with intermediate hyper-
glycaemia at baseline, and for some of the secondary 
outcomes such as cost per mm Hg reduction in systolic 
BP. ICER will be conducted if a significant impact on the 
outcomes is observed. Moreover, all costs and (statistically 
significant) outcomes, both primary and secondary, will 
be presented separately in a cost–consequence analysis.
Willingness to pay/contingent valuation study
We will conduct a willingness to pay (WTP) study in order 
to elicit maximum monthly amount of money each partic-
ipant or household would be willing to pay if an mHealth 
service on diabetes and NCD risk factors’ prevention and 
management (ie, weekly voice messages) was available.
WTP studies are widely used in order to elicit monetary 
value of a service or good not available in the market.27–30 
In the Bangladesh context, Shariful Islam et al in a recent 
study estimated WTP of patients with T2DM for receiving 
messages for increasing adherence to treatment.31 
Similar to Shariful Islam et al, we will use an open-ended 
contingent valuation (CV) method,27 30 32 asking partici-
pants through an open-ended question how much they 
would be willing to pay monthly to receive voice messages 
related to diabetes and NCD risk factors’ prevention 
and management, if such a service was available. Open-
ended CV is a more flexible approach and avoids starting 
point bias or range bias introduced by other methods 
such bidding game and payment cards.27 The theoretical 
framework defined by O’Brien and Gafni28 for CV studies 
will be used to design the study.
WTP questions will be asked from all the participants 
at the end-line impact evaluation survey. WTP values 
will be compared across different groups, for example, 
based on exposure to the interventions (ie, among those 
exposed to mHealth or exposed to participatory groups 
and participants who have not been exposed to either of 
these interventions) or health condition (people diag-
nosed with diabetes or other NCDs and others). In addi-
tion, for each participant, detailed individual-level and 
household-level socioeconomic characteristics will be 
collected to examine the extent to which WTP values will 
vary by socioeconomic status of participants.
Equity impact of the d-Magic interventions
In addition to measuring efficiency/cost-effectiveness of 
the D-Magic interventions, an analysis of equity impact 
of the interventions will be conducted to assess whether 
impacts/gains from the intervention are equitably 
shared among the target population. This will be done 
through subgroup analyses of the primary and secondary 
outcomes based on the socioeconomic status of the target 
population.
Identiication, measurement and valuation of resource use
The cost-effectiveness and cost–consequence of the 
D-Magic interventions will be measured from a societal 
perspective33 34; measuring the economic impact for all 
parties affected by the interventions, including imple-
menting agency (or programme costs), public healthcare 
providers (at both local and national levels) and users, who 
are the intervention participants and their households. 
The following sections provide a detailed description 
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of the proposed methods for measuring and valuing 
programme costs, healthcare provider costs and partic-
ipants/household costs. Programme costs include those 
incurred by the implementing agency or programme 
provider, that is, Diabetic Association of Bangladesh. 
The healthcare provider costs are those incurred by the 
government health facilities in the study area including 
community clinics, Health and Family Welfare centres 
and Upazila Health Complex/hospitals. The household 
or user costs include those incurred by participants and 
their households. Table 1 provides an overview of the 
financial and economic costs to be employed in the 
economic evaluation of the D-Magic interventions.
Programme-related costs
Direct and indirect costs of designing and implementing 
mHealth, community mobilisation and HSS interventions 
will be estimated using a combination of activity-based 
costing35 and ingredients approach.36
Financial or expenditure data
Programme costs are mainly financial or accounting costs, 
which are collected prospectively from the project accounts 
or expenditure records of the implementing partner and 
entered (generally, on an annual basis) to an MS Excel 
data capture tool. The tool contains different sections/
worksheets that will allow the categorisation of costs into 
line items (ie, staff, materials, capital and joint costs), start 
up and implementation costs of the interventions and 
costs associated with the different programme compo-
nents, that is, mHealth, community mobilisation, HSS, and 
monitoring and evaluation. Key informant interviews with 
project leads and monthly/quarterly staff time sheets will be 
used to allocate joint costs between the programme compo-
nents. The summary worksheets in the cost data capture 
tool present the costs by programme component (eg, 
mHealth, community mobilisation and HSS), summarise 
the total cost data per intervention, allows effect data to be 
entered and estimates the cost-effectiveness results.
Table 1 Overview of resource use and costs measures included in the economic evaluation of the D-Magic interventions
Perspective/cost 
category 
Type of 
costs Description Sources Sample size
Provider 
  Programme/
  implementing 
agency
Direct Costs of implementing 
mHealth, community 
mobilisation and HSS 
interventions.
1. Project accounts of the 
implementing agencies.
2. Interviews with the project staff.
NA
Indirect The opportunity cost 
of volunteer experts 
attended the mHealth 
design meetings, 
donated items, etc.
1. Project records on numbers of 
meeting, attendants, etc.
2. Published reports on local 
wage information based on skill 
category.
3. Field ofices’ inventory 
information.
1. All meetings held and 
number of people attended 
in the meetings.
2. The list of all equipment in 
the ield ofices.
  Public healthcare 
providers
Direct Changes in utilisation of 
T2DM and NCD-related 
services at the public 
health facilities in the 
study area.
1. Detailed audit and costing study 
of the health facilities.
2. Baseline and end-line cross-
sectional surveys (for information 
on changes in costs of 
health care seeking).
1. Random sample of health 
facilities at different levels in 
both intervention and control 
areas.
2. All participants in the study.
Indirect The opportunity cost of 
the time spent by the 
healthcare providers 
attending HSS meetings.
1. Project records on numbers of 
meeting, attendants, etc.
2. Published reports on local 
wage information based on skill 
category.
All meetings held and number 
of people attended in the 
meetings.
Participants/
households 
Direct Household expenditure 
on food and non-food.
Household consumption 
expenditure survey.
A random sample of 300 
households in the study area
Costs of health 
care seeking for the 
participants and their 
households.
Baseline and end-line cross-
sectional surveys.
All participants in the study.
Indirect Opportunity cost of 
participation in the 
groups.
Group participants survey. A random sample of 312 group 
participants (both male and 
female).
HSS, health system strengthening; NA, not applicable; NCD, non-communicable diseases; T2DM, type 2 diabetes mellitus. 
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Donated items and opportunity costs
Some items, such as donated items and volunteer time, 
are not captured in the accounting system and need to 
be converted to economic costs using their market value 
and then entered into the data capture tool.37–39 Poten-
tial donated items are equipment donated by the imple-
menting agency (ie, purchased by previous projects and 
used in the D-Magic project). The donated items will 
be identified through key informant interviews with the 
project leads.
The majority of volunteer time is related to designing 
messages for the mHealth intervention, where several 
meetings were held with experts who were volunteers. 
Detailed information regarding these meetings, including 
the number of meetings, their duration and the partic-
ipants, is being documented by the project. The oppor-
tunity cost of the time invested by the experts will be 
measured as a proportion of their salary or a salary equiv-
alent using published national/local wage rate reports.
Public healthcare providers costs
The D-Magic project is likely (at least in the short term) to 
increase seeking care for diabetes, other NCDs and NCD 
risk factors such as hypertension, particularly demand for 
services such as testing and treatment for hypertension, 
diabetes and prediabetes, or seeking advice or treatment 
for weight control. In addition, there is a time (opportu-
nity) cost of direct involvement in the HSS activities for 
the healthcare providers (table 1).
Cost of changes in demand for services
The costs to public healthcare providers in the project 
area due to increased (or any changes in) demand for 
their services will be estimated. A mapping of the health-
care providers in the study area has been completed 
and 20 functional governmental healthcare facilities, 
at different levels, have been identified. These facilities 
included 14 Community Clinics, 3 Health and Family 
Welfare centres and 3 Upazila Health Complex/Hospi-
tals. A sample of 11 health facilities including 8 commu-
nity clinics and 2 Health and Family Welfare centres (with 
equal numbers in control and intervention clusters), as 
well as 1 Upazila Health Complex/Hospital (which cover 
both control and intervention areas) was selected for 
baseline audits of diabetes and NCD services, estimating 
their resource utilisations and unit costs. Similar audits 
and cost data collection will be conducted for the same 
facilities post intervention in order to assess the changes 
in NCD service utilisation attributable to the D-Magic 
interventions. This data will be complemented by health-
seeking behaviour information collected from the study 
participants in control and interventions clusters at the 
D-Magic end-line impact evaluation survey. Differences in 
service utilisation between intervention and control areas 
will be attributed to the D-Magic interventions.
A simple audit and cost-capture tool was developed 
for facility data collection and piloted with facilities at 
different levels. Data from the cost-capture tool will be 
complemented by the existing data from the facility 
reports and published data. Costs of services provided 
by the facilities will be estimated using a step-down 
approach.40
Any change in demand for services provided in the facil-
ities other than those mentioned above and the services 
not covered by them, in intervention areas compared with 
the control, will be identified during the trial’s routine 
monitoring and end-line impact evaluation survey. Any 
cost of that change in demand will be calculated using 
published data on the unit costs of those services.
Opportunity cost of HSS activities
Moreover, as discussed earlier, HSS activities include 
several training sessions for healthcare providers in 
prevention, diagnosis and treatment of T2DM. Infor-
mation on the number of meetings, their duration and 
participation is being documented by the project. The 
opportunity cost of the time spent by the providers will 
be measured as a proportion of their salary for formal 
providers or as a salary equivalent, for informal providers.
Participants and their household costs
D-Magic interventions may influence participants and 
their households’ costs in a number of ways. These 
include changes in health-seeking behaviour, and 
changes in household lifestyles that might affect food and 
non-food consumption patterns and spending as well as 
time spent engaging in physical activities. It also includes 
the time (opportunity) cost of participation in the PLA 
group meetings and participating in the actions taken by 
the groups (table 1).
Healthcare-seeking costs
D-Magic may increase the participants and their house-
holds’ seeking advice and care from both formal and 
informal providers for testing and treatment for hyper-
tension, diabetes, prediabetes and other NCDs. Infor-
mation on costs of care-seeking is collected from all the 
participants recruited in the project, at the baseline and 
end-line evaluation surveys. This information will be 
complemented by the data collected from the house-
hold consumption expenditure survey. The difference in 
spending for the participants and their households will 
be calculated and compared between intervention and 
control areas.
Changes in household food and non-food expenditure
Changes in food and non-food expenditure will be 
captured in a comprehensive household consumption 
and expenditure survey. The survey will be conducted 
on a random subsample of 300 households (100 per trial 
arm) at the end of intervention period. The changes in 
the expenditure will be compared between interventions 
and control areas.
Opportunity cost of participation in the interventions
Participating in the PLA group meetings incur some costs 
to the participants and their family. These costs include 
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the direct costs (eg, cost of getting to the group) and time 
cost of group participation (eg, travel time and time spent 
in the group) and participating in the actions taken by 
the group, or changing health and lifestyle behaviours. 
Information on the potential direct and time costs will 
be collected through a subsample survey of 312 group 
participants (both male and female), randomly selected. 
Sample size for the survey was primarily calculated to 
give sufficiently accurate estimate of group participants’ 
characteristics.
Cost-effectiveness and cost–consequence analyses
Economic evaluation will be conducted as a within-trial 
analysis using the intention-to-treat results, and will be 
presented in terms of ICERs, calculated as the differ-
ence in total costs of mHealth and community mobil-
isation interventions (plus HSS activities) versus HSS 
activities only (or control), divided by the difference in 
mean effects of each interventions versus control.41 42 As 
mentioned previously, ICERs will be evaluated in terms 
of cost per case of intermediate hyperglycaemia and 
T2DM prevented and cost per case of T2DM prevented 
among individuals with intermediate hyperglycaemia at 
baseline, and for some of the secondary outcomes such 
as cost per mm Hg reduction in systolic BP. In addition 
to ICERs, the economic evaluation will be presented 
as a cost–consequence analysis where the incremental 
costs and all statistically significant outcomes will be 
listed separately, allowing policy-makers to compare 
the costs and all impacts/gains of the D-Magic inter-
ventions. Cost–consequence analysis has been recom-
mended for complex public health interventions, such 
as D-Magic, that have multiple health and non-health 
impacts, which are difficult to measure in a common 
outcome unit.42 43
All costs will be presented in 2017 prices in Bangla-
deshi Taka and International Dollars (INT$). All 
costs will be adjusted for inflation using the Bangla-
deshi Consumer Price Index and will be converted to 
2017 INT$ using the purchasing power parity conver-
sion factor for Bangladesh. Moreover, both costs and 
outcomes will be discounted using a standard discount 
rate of 3%, as recommended by WHO-CHOICE44 and 
the Gates/IDSi Reference Case for Economic Evalua-
tion.45 The impact of uncertainty in key parameters on 
the cost-effectiveness results will be assessed through a 
series of deterministic and probabilistic sensitivity anal-
yses. Reporting of the study design, analytical methods 
and findings will follow the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS) 
statement.46 The D-Magic interventions will be judged 
to be cost-effective and affordable (though, indirectly) 
against the WHO-CHOICE recommendation,44 as well 
as recently developed cost-effectiveness thresholds.47
The possibility of conducting an extended cost-ef-
fectiveness analysis48 alongside modelling national 
scale up of the D-Magic interventions will be explored. 
Moreover, we will explore the possibility of running 
a long-term cost-effectiveness analysis using decision 
analytical modelling based on the relevant outcomes 
such as systolic BP, body mass index (if statistically 
significant) to predict future economic impacts from 
implementing the D-Magic interventions on the target 
population.
strengths and limitations of the study
In order to increase transparency and minimise bias, 
publication and peer review of economic evaluation 
protocols is encouraged. This study reports planned 
data collection and analyses alongside a complex public 
health trial. The study will contribute to the scarce 
cost-effectiveness evidence on mHealth and community 
mobilisation interventions for preventing diabetes and 
NCDs.
Furthermore, adopting a cost–consequence anal-
ysis approach makes it possible to report all health and 
non-health impacts of the D-Magic interventions, in addi-
tion to ICERs, which can assist policy-makers to make 
informed decisions in designing or implementing similar 
complex interventions. Incorporating equity impact 
analysis and CV are other strengths of this study, which 
provide useful information for future scale-up of the 
interventions.
The study design has one limitation. The D-Magic 
trial is not powered to test the differences between the 
mHealth and community mobilisation interventions 
due to the large sample size required and the resources 
available for the trial. However, the possibility of a 
direct comparison between the two interventions will 
be explored.
Patient and public involvement
Patients and public were not involved in the process of 
this study. Patients and public will be informed of the 
study results via peer-reviewed journals, conference and 
local dissemination meetings.
dissemination
The findings of this study will be disseminated through 
different means within academia and the wider policy 
sphere.
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